Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | FTO | Q9C0B1 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 3/20 | 0.81 |
| ▸ | THRB | P10828 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.81 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12849250 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL150459 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL30142606 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL12083012 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL22215232 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL150460 | 1.00 | KDM4E (1.00) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| Carbamic Acid SCHEMBL2453716 | 0.92 | KDM4E (0.85) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL31663895 | 0.92 | KDM4E (0.85) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| Ether SCHEMBL7982613 | 0.91 | KDM4E (0.83) | KDM4EMEN1KMT2ACYP2D6TP53 | |
| SCHEMBL4104614 | 0.90 | KDM4E (0.81) | KDM4EMEN1KMT2ACYP2D6TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0946560-A1 | METHOD OF PREPARATION OF PHYSOSTIGMINE CARBAMATE DERIVATIVES FROM ESEROLINE ETHERS | HOECHST MARION ROUSSEL, INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027096-A1 | METHOD OF PREPARATION OF PHYSOSTIGMINE CARBAMATE DERIVATIVES FROM ESEROLINE ETHERS | HOECHST MARION ROUSSEL, INC. (US) | 1998-06-25 | — | — | WO | claimed |
| EP-0538248-B1 | TETRAHYDROISOQUINOLINYLCARBAMATES OF 1,2,3,3A,8,8A-HEXAHYDRO-1,3A,8-TRIMETHYLPYRROLO [2,3-B]INDOLE | HOECHST MARION ROUSSEL INC (US) | 1998-02-11 | — | — | EP | claimed |
| US-5665880-A | Method of preparation of physostigmine carbamate derivatives from eseretholes | HOECHST MARION ROUSSEL, INC. (US) | 1997-09-09 | — | — | US | claimed |
| US-5547977-A | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8(and 1,3A,8)-di (and Tri) methylpyrrolo (2,3-B) indoles | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1996-08-20 | — | — | US | claimed |
| EP-0538248-A4 | — | — | 1994-08-03 | — | — | EP | claimed |
| EP-0538248-A1 | TETRAHYDROISOQUINOLINYLCARBAMATES OF 1,2,3,3A,8,8A-HEXAHYDRO-1,3A,8-TRIMETHYLPYRROLO [2,3-B]INDOLE | HOECHST MARION ROUSSEL, INC. (US) | 1993-04-28 | — | — | EP | claimed |
| US-5187165-A | Eseroline derivatives; cholinergic agents; antidepressants | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-02-16 | — | — | US | claimed |
| WO-1992000072-A1 | TETRAHYDROISOQUINOLINYLCARBAMATES OF 1,2,3,3A,8,8A-HEXAHYDRO-1,3A,8-TRIMETHYLPYRROLO[2,3-B]INDOLE | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-01-09 | — | — | WO | claimed |
| US-4791107-A | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-12-13 | — | — | US | claimed |
| EP-0253372-A2 | 1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indoles, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-01-20 | — | — | EP | claimed |
| WO-2020227385-A1 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING FIBROSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-12 | — | — | WO | disclosed |
| US-20120295946-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | National Institute of Health (NIH) | 2012-11-22 | — | — | US | disclosed |
| US-20120295946-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | National Institute of Health (NIH) | 2012-11-22 | — | — | US | disclosed |
| US-8258172-B2 | Agents useful for reducing amyloid precursor protein and treating dementia and methods of use thereof | RAPTOR PHARMACEUTICAL CORP (US) | 2012-09-04 | — | — | US | disclosed |
| US-5206260-A | Cholinesterase inhibitors | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
| US-5187165-A | Eseroline derivatives; cholinergic agents; antidepressants | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1993-02-16 | — | — | US | disclosed |
| WO-1992000072-A1 | TETRAHYDROISOQUINOLINYLCARBAMATES OF 1,2,3,3A,8,8A-HEXAHYDRO-1,3A,8-TRIMETHYLPYRROLO[2,3-B]INDOLE | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-01-09 | — | — | WO | disclosed |
| US-4791107-A | Memory enhancing and analgesic 1,2,3,3A,8,8A-hexahydro-3A,8 (and) 1,3A,8)-di(and tri)methylpyrrolo(2,3-B)indoles, compositions and use | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0253372-A2 | 1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indoles, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295946-A1 | Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof | APP, BACE1, PSEN1 | KDM4E 3926/4885MEN1 2576/4885KMT2A 4287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.